Study S000497

Efficacy of Semaglutide in Improving Neurological Outcomes After Endovascular Thrombectomy for Acute Ischemic Stroke: A Randomized Double-Blind Controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07030621
Acronym: STARS
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: NOT_YET_RECRUITING
Enrollment: 436
Start: 2025-07-01
Primary completion: 2027-07-31
Lead sponsor: RenJi Hospital
Conditions: Acute Ischemic Stroke
Interventions: DRUG:Semaglutide 0.5 mg; DRUG:Normal Saline
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

mRS at 90-days [90 days postoperatively]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0017649	Semaglultide targets Spp1+ microglia/macrophage to attenuate neuroinflammation following perioperative stroke. Li Y, Journal of neuroinflammation	2025	Preclinical	PMID 40426210 DOI	registry reference RESULT:40426210
R0002614	Effects of GLP-1 receptor agonists on neurological complications of diabetes. García-Casares N, Reviews in endocrine & metabolic disorders	2023	Systematic review	PMID 37231200 DOI	registry reference RESULT:37231200
R0018500	The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma. Cui QN, British journal of pharmacology	2022	Narrative review	PMID 34519040 DOI	registry reference RESULT:34519040
R0022278	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Marso SP, The New England journal of medicine	2016	Randomized trial	PMID 27633186 DOI	registry reference RESULT:27633186